Zonisamide


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
History of hypersensitivity to sulfonamides.
Special Precautions
Patient with decreased hepatic mitochondrial activity or inborn errors of metabolism; risk factors for nephrolithiasis (e.g. family history, previous stone formation, hypercalciuria), predisposition to acidosis (e.g. severe respiratory disease, status epilepticus, diarrhoea, surgery, ketogenic diet, other drugs); history of eye disorders. Avoid abrupt withdrawal. Not recommended in renal (GFR <50 mL/min) and severe hepatic impairment; in children who are underweight and have decreased appetite. Concomitant use with carbonic anhydrase inhibitors and drugs with anticholinergic activity in adults; avoid concomitant use in children. Renal and mild to moderate hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, sedation, and difficulty with concentration; if affected, do not drive or operate machinery. Ensure adequate hydration or fluid intake, particularly in children. Avoid exposure to excessive temperatures and strenuous physical activity. Monitoring Parameters Monitor serum bicarbonate levels before initiation and periodically during treatment; metabolic profile (particularly BUN and serum creatinine); ammonia levels (if signs or symptoms of encephalopathy occur); pancreatic lipase and amylase levels (in patients who develop pancreatitis); serum creatine phosphokinase and aldolase levels (in those who experience severe muscle pain or weakness with or without fever). Assess for signs and symptoms of emergence or worsening of suicidal thoughts or behaviour, depression and/or unusual changes in behaviour; decreased sweating and increased body temperature specifically during hot or warm weather (particularly in children).
Adverse Reactions
Significant: Suicidal ideation and behaviour, CNS effects (e.g. fatigue, sedation, somnolence, depression, psychosis, speech or language problems, difficulty with concentration), acute myopia, secondary angle-closure glaucoma, rash; hyperammonaemia with or without encephalopathy; hyperchloraemic, non-anion gap, metabolic acidosis (dose-dependent); elevated serum creatinine and BUN, nephrolithiasis, pancreatitis, rhabdomyolysis; decreased sweating, increased body temperature and levels of AST, ALT, gamma-glutamyltransferase (GGT) and bilirubin (particularly in children). Blood and lymphatic system disorders: Ecchymosis. Eye disorders: Diplopia, nystagmus. Gastrointestinal disorders: Nausea, dyspepsia, diarrhoea, abdominal pain, constipation, vomiting. General disorders and administration site conditions: Flu-like illness, pyrexia, peripheral oedema. Immune system disorders: Hypersensitivity. Investigations: Decreased bicarbonate levels and weight; increase blood creatine phosphokinase. Metabolism and nutrition disorders: Anorexia, decreased appetite. Nervous system disorders: Dizziness, ataxia, paraesthesia, tremor, bradyphrenia, memory impairment, attention disturbance. Psychiatric disorders: Agitation, anxiety, irritability, confusional state, mood swings, insomnia, affect lability. Skin and subcutaneous tissue disorders: Pruritus, alopecia.
Potentially Fatal: Drug reaction with eosinophilia and systemic symptoms (DRESS) or multiorgan hypersensitivity reaction; heatstroke requiring hospitalisation, weight loss which may lead to deterioration of general condition (particularly in children). Rarely, serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme), haematologic disturbances (e.g. agranulocytosis, aplastic anaemia), fulminant hepatic necrosis.
Drug Interactions
May increase the risk of metabolic acidosis, hyperammonaemia, and kidney stone formation with other carbonic anhydrase inhibitors (e.g. topiramate, acetazolamide). Risk of heat-related disorders may be increased with carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g. haloperidol, diphenhydramine, clomipramine, oxybutynin), especially in children. May decrease exposure and serum concentration with CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital, rifampicin). May cause additive CNS effects (e.g. fatigue, somnolence) with other CNS depressants.
CIMS Class
Anticonvulsants
ATC Classification
N03AX15 - zonisamide ; Belongs to the class of other antiepileptics.
Disclaimer: This information is independently developed by CIMS based on zonisamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in